Research Article

Severity of Vitamin D Deficiency Predicts Mortality in Ischemic Stroke Patients

Table 2

Comparison of subgroups distinguished according to the modified Rankin scale at discharge.

Modified Rankin scale at discharge
0-1 (no significant disability) ()2-3 (mild/moderate disability) ()4-5 (moderately severe and severe disability) ()6 (death) ()

Age (years)^^^^^^
Gender (men/women)48/3733/3518/4510/14
History of previous stroke (/%)14 (16.5)14 (20.6)10 (15.9)4 (16.7)
Concomitant diseases
 Hypertension (/%)71 (83.5)60 (88.2)54 (85.7)18 (75.0)
 Coronary artery disease (/%)26 (30.6)15 (22.1)20 (31.8)8 (33.3)
 Valvular diseases (/%)7 (8.2)7 (10.3)9 (14.3)1 (4.2)
 Atrial fibrillation (/%)17 (20.0)15 (22.1)27 (42.9)^^11 (45.8)^
 Obesity (/%)18 (21.2)8 (12.8)16 (25.4)2 (8.3)
 Diabetes (/%)25 (29.4)22 (32.3)26 (41.3)11 (45.8)
 Hypercholesterolemia (/%)37 (43.5)35 (51.5)29 (46.0)6 (25.0)
Statin therapy (/%)36 (42.3)26 (38.2)22 (34.9)8 (33.3)
Active smokers (/%)20 (23.5)13 (19.1)11 (17.5)1 (4.2)
Estimated glomerular filtration rate (eGFR) (mL/min/1. 73 m2)
 mL/min/1. 73 m2 (/%)20 (23.5)22 (32.3)32 (50.8)^^^12 (50.0)^
C-reactive protein (CRP) (mg/L)3.8 (1.3–9.3)4.3 (2.6–9.1)4.2 (1.7–10.6)4.3 (8.5–8.5)
Calcium (mg/dL)
Phosphorus (mg/dL)1.13 (0.98–1.31)1.16 (0.94–1.43)1.11 (0.96–1.32)1.05 (0.98–1.24)
Intact parathyroid hormone (iPTH) (pg/mL)36.5 (21.7–49.8)37.2 (24.9–57.1)46.9 (31.1–66.9)^47.4 (35.2–60.7)
 pg/mL (/%)10 (11.8)15 (22.1)17 (27.0)6 (25.0)
Intact fibroblast growth factor 23 (iFGF23) (pg/mL)42.3 (10.6–77.2)58.7 (17.8–92.4)51.5 (25.3–92.2)48.2 (19.9–102.1)
 pg/mL (/%)37 (43.5)39 (57.4)33 (52.4)11 (45.8)
25-OH-D (ng/mL)9.6 (4.8–14.7)8.4 (4.9–13.4)7.2 (3.0–12.1)6.3 (3.4–9.8)
 ng/mL (/%)48 (56.5)43 (63.2)42 (66.7)18 (75.0)^
One-year survival (%)80 (94.1)58 (85.3)45 (71.4)^^^
Two-year survival (%)60 (91.7)40 (82.1)27 (57.8)^^^

^; ^^; ^^^ vs. minor stroke (0-1).